Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRL 790

Drug Profile

IRL 790

Alternative Names: IRL790

Latest Information Update: 30 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Integrative Research Laboratories
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 28 Aug 2019 Safety, efficacy and pharmacokinetic data from a phase IIa trial in Parkinson's disease presented by Integrative Research Laboratories
  • 27 Aug 2019 Integrative Research Laboratories plans a phase IIb/III trial for Parkinson's disease (PO), in the first half of 2020
  • 18 Jun 2019 Integrative Research Laboratories completes a phase II trial in Parkinson's disease (Adjunctive treatment) in Sweden and United Kingdom (PO) (NCT03368170) (EudraCT2017-003458-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top